FDA grants En­her­tu tu­mor-ag­nos­tic ac­cel­er­at­ed ap­proval

The FDA on Fri­day gave Dai­ichi Sankyo and As­traZeneca’s an­ti­body-drug con­ju­gate En­her­tu a tu­mor-ag­nos­tic in­di­ca­tion un­der ac­cel­er­at­ed ap­proval. It’s the first such ap­proval for a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER